Your Basket
Your Basket
There are no funds in your basket. To add funds to your basket use the Green Plus Icon wherever you see it next to a fund.
Fund name
Aberdeen American Growth  
Fidelity American  
Schroder UK Mid 250  
M&G Recovery  
Jupiter Merlin UK Growth  
Close Basket Open basket

Login

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
 

Investors turn their backs on bond funds

Income-seeking investors are beginning to favour equity managers for a source of yield over those focused on fixed interest.

By Joshua Ausden, News Editor, FE Trustnet Follow
Tuesday August 28, 2012


No fixed interest funds are among the top-10 sellers of the last month, according to FE inflows data, demonstrating an increase in risk appetite following a strong run for equity markets in recent weeks.

While the likes of M&G Optimal Income, M&G Corporate Bond and M&G Strategic Corporate Bond all make the overall top-10 list over three and six months, star manager Richard Woolnough has experienced a decrease in demand of late.

Aviva Inv Corporate Bond and Henderson Fixed Interest Monthly Income, which have also proved popular in 2011, have also seen their inflows slow in the last month. 

Income remains the biggest theme, although investors appear more willing to try their chances with the equity markets rather than through a less volatile bond fund.

Invesco Perpetual High Income, Newton Asian Income and the HSBC FTSE All Share Index funds are all among the best sellers.

Multi-asset funds also remain popular, with the Henderson Cautious Managed and Newton Real Return funds included in the top-10. 

Overall best-selling funds over 1-month

Henderson - Cautious Managed 
Invesco Perp - High Income 
Newton - Real Return 
Baillie Giff - Diversified Growth 
Baring - Multi Asset 
Newton - Asian Income 
BlackRock - Cautious Portfolio 
HSBC - FTSE All Share Index 
Cazenove - UK Opportunities 
First State - Global Emerging Markets Leaders 

Source: FE Analytics

The trend was also evident in The Share Centre’s top-10 best-sellers list for July which, for the first time since April, did not include a single fixed interest portfolio. 

FE Alpha Manager Neil Woodford’s Invesco Perpetual High Income fund once again featured, sitting alongside the L&G UK Index and Newton Global Higher Income funds in the top-three. 

The Share Centre’s best-selling funds in July

Legal & General UK Index 
Invesco Perpetual High Income  
Newton Global Higher Income 
Legg Mason Japan Equity  
AXA Framlington Biotech 
Jupiter Global Managed  
Schroder Asian Income Maximiser 
BlackRock Gold & General 
Fidelity Enhanced Income 
Threadneedle American Smaller Companies 

Source: FE Analytics

"July’s top-10 funds clearly show that investor appetite for additional income shows no sign of diminishing, as does investors' interest in seeking and exploiting opportunities from outside of the UK shorelines," said Andy Parsons, head of investment research at The Share Centre. 

"It is also interesting to note that this is the first time for a couple of months that no debt fund, neither sovereign nor corporate, has appeared within the top-10." 

Parsons says the increasing risk appetite and focus on income and geographical diversification is typified by the fund that takes the number-three spot. 

"In third place was the Newton Global Higher Income fund. With a truly global investment mandate, strong track record and an impressive manager at the helm in the shape of James Harries, investors have clearly shown appetite for seeking income away from the core traditional UK Equity Income sector," he explained. 

"In fourth and fifth place were two funds that clearly demonstrated an appetite for risk, sector and geographical specialism."

"The Legg Mason Japan Equity fund specifically focuses on smaller companies within the region, whilst the AXA Framlington Biotech fund offers investors an opportunity to benefit from those companies involved in the biotechnology, genomic and medical research industries."

"By the very nature of the industry, this fund will always have a high exposure to the US," he added. 

Global markets have risen considerably of late, with the FTSE 100 and S&P 500 up 11 and 8 per cent respectively since 1 June.

While investors appear to be becoming more bullish, a number of high-profile industry experts remain wary. A recent FE Trustnet article highlighted the cautious views of Aberdeen’s Bruce Stout, MAM’s James Sullivan and Cazenove’s Robin McDonald, to name but a few. 



 
Add your comment
Step 1: Tell us what you think...
 

Step 2: Prove you're not a robot...
You don't have to do this every time you submit a comment.

Login or register free and you won't see it again.
Enter the words above:
Step 3: Submit your comment...
Submit
 
Be the first to comment on this Research Article.

 

Follow FE Trustnet

Video Headlines

More Videos

Gray: Market rally has made me more bearish than ever

GMT 15:30 | 30-Apr-2013

From the analyst's desk

GMT 10:00 | 29-Apr-2013

 
Poll

Would you be concerned if a manager of a fund you owned took charge of another portfolio as well?

Yes

No

Vote

 
 
  • Stay connected with FE trustnet
  • Authorised and Regulated by the
    Financial Services Authority
  • © Trustnet Limited 2013. All Rights Reserved.
  • Please read our Terms of Use / Disclaimer
    and Privacy and Cookie Policy.
  • Data supplied in conjunction with Thomson Financial Limited,
    London Stock Exchange Plc, StructuredRetailProducts.com
    and ManorPark.com